By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Phase 3 Clinical Trial to Initiate in 4Q19 On October 2, 2019, ContraFect Corp. (NASDAQ:CFRX) announced that following a successful ‘end-of-Phase 2’ meeting with the FDA the company is planning to conduct a single Phase 3 clinical trial of...
NASDAQ:SNES Background SenesTech Inc., head-quartered in Flagstaff, AZ was founded in 2004. The firm has developed a solution for managing pests through fertility control. Their current marketed product, ContraPest®, a liquid bait, limits fertility in male and female rats. ContraPest is the first and only...
By David Bautz, PhD NYSE:OGEN READ THE FULL OGEN RESEARCH REPORT Business Update Poster on Phase 2 Trial of AG013 Presented at ESMO 2019 On September 30, 2019, Oragenics, Inc. (NYSE:OGEN) announced the presentation of a poster discussing the ongoing Phase 2 clinical trial of AG013 in severe oral mucositis (SOM) at...
By David Bautz, PhDTSX:MDNA.TOREAD THE FULL MDNA.TO RESEARCH REPORTBusiness UpdateUpdated Data from Phase 2b Trial Presented at Targeting Innate Immunity CongressOn September 25, 2019, Medicenna Therapeutics Corp. (TSX:MDNA) announced the presentation of updated clinical data from the ongoing Phase 2b trial of MDNA55, an IL-4 targeted toxin, in patients...
By Brian Marckx, CFANASDAQ:ARWRREAD THE FULL ARWR RESEARCH REPORTPipeline Highlights: APOC3/ANG3 Topline Data, Orphan Desig. JNJ-3989 in Ph2b, Cohort 12 Data Upcoming. And More… Arrowhead (NASDAQ:ARWR) continues to make rapid progress across most of their pipeline. There has been no shortage of positive product development related events as...
By John Vandermosten, CFANASDAQ:AZRXREAD THE FULL AZRX RESEARCH REPORT AzurRx BioPharma, Inc. (NASDAQ:AZRX) announced Phase II OPTION trial results for MS1819 in cystic fibrosis (CF) patients. Data provided was sparse, but the summary highlighted the positive safety profile for MS1819 and the utility of the drug in comparison with...
By John Vandermosten, CFANYSE:CVM While CEL-SCI (NYSE:CVM) has experienced outstanding performance over the last several quarters due to the anticipated readout of Multikine in the IT-MATTERS clinical trial, the company also has a platform technology in development that has impressive potential in treating a number of human diseases. This...
By John Vandermosten, CFANASDAQ:ACHV Achieve Life Sciences, Inc. (NASDAQ:ACHV) held its first investor day following the read out of the ORCA-1 trial on September 20, 2019. The event was introduced by CFO John Bencich and included a roundtable discussion moderated by analysts Michael Higgins of Ladenburg Thalmann and Jason McCarthy...
By Steven Ralston, CFACSE:HUGE.CN | OTC:FSDDFREAD THE FULL HUGE.CN RESEARCH REPORT FSD Pharma Inc. (CSE:HUGE.CN) (OTC:FSDDF) is a cannabis-platform company which is targeting many verticals that compose the legal cannabis industry. The platform can be bifurcated into two components. One, management is concentrating on the cultivation, processing and distribution of...
By David Bautz, PhDNASDAQ:TNXPREAD THE FULL TNXP RESEARCH REPORTBusiness UpdatePipeline ExpansionIn the past few months, Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) has announced the addition of a number of new programs to its clinical and pre-clinical pipeline, including additional indications for its lead development compound TNX-102 SL. Below we give...